Skip to main content
Clinical Trials/NCT03112265
NCT03112265
Completed
N/A

Using Neuroimaging to Understand Children's Mental Health and Treatment Outcomes

Harvard University1 site in 1 country100 target enrollmentJanuary 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Anxiety
Sponsor
Harvard University
Enrollment
100
Locations
1
Primary Endpoint
Change from Baseline Emotional Go/No-Go Task at End of Treatment
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The study will compare the impact of Child STEPs versus usual school-based therapy on neural and companion behavioral measures of self-regulation.

Detailed Description

This project will implement and evaluate the Child STEPs treatment approach as compared to "treatment as usual" (known as Usual Care or UC) through a randomized controlled trial (RCT) at eight K-8 public schools. The STEPs model has two components: (1) a modular protocol that combines 33 modules-i.e., descriptions of common elements within evidence-based therapies for anxiety, depression, post-traumatic stress, and conduct problems; and (2) a web-based system for monitoring student responses to treatment and providing weekly feedback to therapists to guide their selection and sequencing of the STEPs modules. The project will examine: (a) whether self-regulation skills at baseline are associated with baseline patterns of mental health and school problems; (b) whether self-regulation skills at baseline predict degree of improvement during treatment; (c) whether self-regulation skills improve from pre-to post treatment, and whether extent of this improvement differs by treatment condition; and (d) whether self-regulation improvement (from pre-to-post treatment) mediates the long-term benefit of treatment.

Registry
clinicaltrials.gov
Start Date
January 2015
End Date
July 31, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

John Weisz

Professor and Primary Investigator

Harvard University

Eligibility Criteria

Inclusion Criteria

  • enrolled in grades 3-7
  • have a primary clinical problem in the areas of anxiety, depression, conduct, or posttraumatic stress
  • clinically elevated problem levels on the Internalizing, Externalizing, Anxious-Depressed, Withdrawn-Depressed, Aggressive Behavior, or Rule-Breaking Behavior scales of the Child Behavior Checklist or Youth Self-Report or on the UCLA Post-Traumatic Stress Disorder Reaction Index.

Exclusion Criteria

  • Mental retardation
  • Pervasive developmental disorder
  • Eating disorder
  • children for whom attention problems or hyperactivity are the primary referral concern
  • active psychosis and/or a suicide attempt in the previous year
  • To participate in the two neuroimaging tasks (Emotion Regulation Task; Emotional Go/No Go Task), participants must be healthy (no major medical illness), right-handed, fluent in English, have no history of neurological impairment (including but not limited to history of loss of consciousness for great than 20 minutes, seizures, stroke, etc.), have normal or corrected to normal vision, and have no contra-indications or risk factors for MRI research (such as braces or metal implants).

Outcomes

Primary Outcomes

Change from Baseline Emotional Go/No-Go Task at End of Treatment

Time Frame: Change over time from Day 1 to end of treatment, assessed up to 40 weeks

Change from Baseline Emotion Regulation Task at End of Treatment

Time Frame: Change over time from Day 1 to end of treatment, assessed up to 40 weeks

Secondary Outcomes

  • Change from Baseline Attentional Bias Task at End of Treatment(Change over time from Day 1 to end of treatment, assessed up to 40 weeks)
  • Change from Baseline Granularity Task at End of Treatment(Change over time from Day 1 to end of treatment, assessed up to 40 weeks)
  • Change from Baseline Early Adolescent Temperament Questionnaire Revised (EATQ-R) at End of Treatment(Change over time from Day 1 to end of treatment, assessed up to 40 weeks)
  • Change from Baseline Behavior Rating Inventory of Executive Function (BRIEF) at End of Treatment(Change over time from Day 1 to end of treatment, assessed up to 40 weeks)

Study Sites (1)

Loading locations...

Similar Trials

Using Neuroimaging to Understand... | Clinical Trial